Abstract
The prevalence of malaria parasite species in parts of Africa is rapidly changing and influenced by detection methods. The natural vector competence and vectorial capacity of African anophelines for human Plasmodium species has only been well described for P. falciparum and is unclear in the context of mixed and non-falciparum infections. Over the course of two clinical trials (2015 and 2019-2020) testing ivermectin for malaria control in the same region of Burkina Faso, we sampled participants’ blood and their households for Anopheles spp. mosquitoes and tested these samples for Plasmodium species. Plasmodium prevalence in participants and their blood samples was high in both trials. While P. falciparum mono-infections comprised most infections in the 1st trial, mixed and non-falciparum infections comprised 27% of infections in the 2nd trial, with notable changes in species present within participants over time. Furthermore, An. gambiae s.l. was the main vector captured, but An. funestus mosquitoes were unexpectedly prevalent in the 2nd trial, and we found that parasite species prevalence differed in abdominal and head+thorax tissues of these two vector species. Most notably, P. falciparum sporozoites were significantly more prevalent than other parasite species in An. gambiae s.l. while P. ovale sporozoites were significantly more prevalent than other parasite species in An. funestus. Our data suggest differential vector competence for Plasmodium species at the study site, which may significantly impact malaria epidemiology, disease prevalence and control efforts.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02509481 & NCT03967054
Clinical Protocols
https://clinicaltrials.gov/study/NCT02509481?term=RIMDAMAL&rank=2
https://clinicaltrials.gov/study/NCT03967054?term=RIMDAMAL&rank=1
Funding Statement
The RIMDAMAL study was funded by grant OPP1116536 from the Bill and Melinda Gates Foundation and the RIMDAMAL II study was funded by grant U01AI138910 from the U.S. National Institutes of Health
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Colorado State University gave ethical approval for this work (IRB numbers: 15-5796H & 18-8083H) Ethics committee/IRB of Comite d'Ethique Institutionnel pour la Recherche en Sciences de la Santé gave ethical approval for this work (EC numbers: A03-2015/CEIRES & A031-2018/CEIRES)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All RIMDAMAL II data will be deposited in ClinEpiDB.org and be available for analysis and download under the terms of set by the website.
